Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026987 · ClinicalTrials.gov registry record · Phase 1
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01026987 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 29 participants.
The verdict
NCT01026987, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.
Interventions
- DRUG G-CSF
- PROCEDURE Leukapheresis
- DRUG AMD3100
- PROCEDURE Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-04-29 |
| Est. Completion | 2016-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026987
The ClinicalTrials.gov registry entry for NCT01026987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which G-CSF is the first listed.
NCT01026987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026987 about?
NCT01026987 is a clinical study titled "Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant". Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.
What is the current status of trial NCT01026987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2010-04-29. Estimated completion is 2016-06-08.
What interventions are being tested in trial NCT01026987?
The interventions under investigation include: G-CSF (DRUG), Leukapheresis (PROCEDURE), AMD3100 (DRUG), Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01026987?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.